Cytek Biosciences, Inc. income statement CTKB

Annual Quarterly

In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, Cytek Biosciences, Inc. reported revenue of $53.2 million, up 1.8% from the same quarter a year earlier. It recorded a net loss of $6.1 million. The operating loss came to $8.4 million, an operating margin of -15.8%.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	208 +5.5%	53 +1.8%	48 +5.6%	44 +6.5%	62 +8.1%	52 +1.5%	46 -2.2%	41 -7.6%	57 -1.3%
Cost of revenue	94 +2.6%	22 -11.0%	20 -8.9%	23 +7.4%	29 +22.8%	25 +10.0%	22 +2.6%	21 -2.5%	24 -5.4%
Gross profit	114 +8.0%	31 +13.3%	28 +18.7%	21 +5.4%	33 -2.3%	28 -5.0%	24 -6.2%	20 -12.4%	34 +1.8%
Research and development	38 +1.2%	9 +4.5%	10 +10.4%	10 -1.2%	9 -7.8%	9 -9.4%	9 -11.7%	10 -0.7%	10 -10.5%
Selling, general and administrative	120 +20.1%	30 +9.0%	30 +16.9%	30 +18.5%	30 +40.9%	28 +18.9%	26 +7.1%	25 +6.1%	21 -6.2%
Operating expenses	158 +15.0%	40 +7.9%	40 +15.2%	40 +13.1%	38 +25.5%	37 +10.5%	34 +1.6%	35 +4.1%	31 -7.6%
Operating income	-44 -38.0%	-8 +8.4%	-11 -7.3%	-18 -23.3%	-6 -287.3%	-9 -116.4%	-11 -24.6%	-15 -39.5%	3 +2279.6%
Pretax income	—	—	—	—	-4 -139.0%	-8 -5048.4%	-7 +5.7%	-11 -25.3%	10 +151.1%
Income tax	41 +1646.4%	-1 +64.6%	1 +143.2%	1 +997.8%	40 +5789.0%	-2 -192.2%	-1 -136.7%	0 +104.8%	1 +148.9%
Net income	—	-6	-12	-19 -65.5%	—	—	—	-11	—
Basic EPS	-0.63 -527.5%	—	—	—	—	—	—	—	—
Diluted EPS	-0.63 -527.5%	—	—	—	—	—	—	—	—
Weighted average shares, basic	129 +0.9%	130 +2.2%	129 +2.0%	129 +0.3%	128 -0.7%	128 -2.6%	127 -3.4%	128 -2.0%	129 -3.3%
Weighted average shares, diluted	129 +0.9%	130 +2.2%	129 +2.0%	129 +0.3%	128 -0.7%	128 -3.9%	127 -3.4%	128 -2.0%	129 -3.3%
Other measures
Depreciation and amortization	8 +4.6%	2 +10.2%	2 +6.3%	2 -0.5%	2 +2.3%	2 +3.6%	2 +4.5%	2 +10.4%	2 +13.7%
EBITDA	-36 -48.3%	-6 +13.3%	-9 -7.5%	-17 -26.7%	-4 -176.4%	-7 -203.5%	-9 -30.0%	-13 -45.0%	5 +224.0%
Interest coverage	-562.56x	-32.40x	-40.57x	-70.47x	—	-18.61x	-25.66x	-51.46x	—
Margins
Gross margin	54.75%	58.63%	58.87%	48.16%	52.92%	52.69%	52.34%	48.62%	58.55%
Operating margin	-21.13%	-15.82%	-23.68%	-41.83%	-9.00%	-17.58%	-23.30%	-36.12%	5.20%
Pretax margin	—	—	—	—	-6.49%	-14.86%	-14.86%	-27.18%	17.96%
Profit margin	—	-11.45%	-25.26%	-42.75%	—	—	—	-27.50%	—
EBITDA margin	-17.34%	-11.85%	-19.51%	-37.61%	-5.95%	-13.91%	-19.15%	-31.60%	8.42%
Effective tax rate	—	—	—	—	—	—	—	—	6.59%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Laboratory Analytical Instruments (SIC 3826)
Listed as: CTKB (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Fremont, CA
SEC filer status: Accelerated filer
SEC CIK: 1831915

Other Laboratory Analytical Instruments companies

All 25 Laboratory Analytical Instruments companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.